Onvansertib + Paclitaxel In TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Invasive Breast Cancer|Unresectable Breast Carcinoma|Locally Advanced Breast Cancer|Metastatic Breast Cancer|Inflammatory Breast Cancer|Triple Negative Breast Cancer (TNBC)|Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Negative Breast Carcinoma
Interventions: DRUG: Onvansertib|DRUG: Paclitaxel
Sponsor: Antonio Giordano, MD
Collaborators: Cardiff Oncology